Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Copenhagen Stock Exchange  >  Novo Nordisk A/S    NOVO.B   DK0060534915

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Copenhagen Stock Exchange
05/23/2016 05/24/2016 05/25/2016 05/26/2016 05/27/2016 Date
355.9 364.4 377.2 372.1 371 Last
2008639 2691348 3579111 2317748 2010541 Volume
-0.89% +2.39% +3.51% -1.35% -0.30% Change
Financials ( DKK)
Sales 2016 114 738 M
EBIT 2016 49 720 M
Net income 2016 38 915 M
Finance 2016 8 861 M
Yield 2016 1,94%
Sales 2017 123 280 M
EBIT 2017 53 774 M
Net income 2017 42 641 M
Finance 2017 11 507 M
Yield 2017 2,15%
P/E ratio 2016 24,04
P/E ratio 2017 21,58
EV / Sales 2016 6,43x
EV / Sales 2017 5,96x
Capitalization 746 661 M
More Financials
Company
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related... 
Sector
Pharmaceuticals
Calendar
06/14 | 01:15amPresentation
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
05/25 NOVO NORDISK A/S : IDegLira receives positive 16-0 vote in favour of approval fr..
05/25 NOVO NORDISK A/S : European shares hit new 4-week high
05/24 NOVO NORDISK A/S : IDegLira receives positive 16-0 vote in favour of approval fr..
05/23 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
05/20 NOVO NORDISK A/S : FDA posts briefing materials prior to Advisory Committee meet..
05/19 NOVO NORDISK A/S : Team Novo Nordisk doing more than just racing
05/17 NOVO NORDISK A/S : files for regulatory approval in the US of long-acting factor..
05/17 NOVO NORDISK A/S : Iran to join insulin producers club in four years
05/16 NOVO NORDISK A/S : files for regulatory approval in the US of long-acting factor..
05/16 EMISPHERE TECHNOLOGIES : Reports First Quarter 2016 Financial Results
More news
Sector news : Pharmaceuticals - NEC
05/28 SUN PHARMACEUTICAL : Pharma Q4 profit seen up 113%, Gleevec may drive US sales
05/28 TAKEDA PHARMACEUTICAL : Receives Positive CHMP Opinion for ADCETRIS (brentuximab..
05/28DJSUBSCRIBERS : Covestro News Reported in April
05/28DJCovestro Eyes Acquisitions, Says Finance Chief - Report
05/28 ASTRAZENECA : S faslodex met primary endpoint in first-line treatment of advance..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/27 European Ad Comm backs AstraZeneca's combo med for T2D
05/25 Ad Comm backs Novo's combo med for T2D
05/18 The Celgene-Agios Partnership Strategy
05/17 Can Orexigen Take Advantage Of Transition Period?
05/16 ARENA INVESTORS : What To Consider As Anti-Obesity Drugs Fizzle
Advertisement
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO.B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions